pembrolizumab + nab-paclitaxel + carboplatin + doxorubicin + cyclophosphamide

This combination consists of five agents frequently used in oncology, specifically immunotherapy (pembrolizumab), microtubule inhibitor chemotherapy (nab-paclitaxel), platinum-based chemotherapy (carboplatin), anthracycline chemotherapy (doxorubicin), and alkylating agent chemotherapy (cyclophosphamide). **Pembrolizumab** is a monoclonal antibody targeting PD-1, inhibiting the interaction with PD-L1/PD-L2 and boosting anti-tumor T-cell activity[1][2][3]. **Nab-paclitaxel** (nanoalbumin-bound paclitaxel) disrupts microtubule function to inhibit mitosis[1][5][7]. **Carboplatin**, a platinum agent, creates DNA crosslinks that inhibit DNA replication and transcription, leading to tumor cell apoptosis[5]. **Doxorubicin** is an anthracycline antibiotic that intercalates DNA and inhibits topoisomerase II, causing DNA damage and apoptosis[5]. **Cyclophosphamide** is an alkylating agent that crosslinks DNA, preventing cell division and inducing apoptosis[5]. This combination is sometimes used in clinical trials for breast cancer and lung cancer[5][1][7], especially triple-negative breast cancer, though not as a single approved regimen—its individual components are approved for various cancers in multiple combinations.

Other names

pembrolizumab + nab-paclitaxel + carboplatin + doxorubicin + cyclophosphamidepembrolizumab, nab-paclitaxel, carboplatin, doxorubicin, cyclophosphamide combination